CJC-1295 with DAC (CJC-1295 DAC)

Long-Acting Growth Hormone Releasing Hormone Analog | Extended Release

Weight: 3,647.28 Da
Half-life: 6-8 days
Chain: 30 amino acids
4 studies
2009 latest
1 recent
Well Studied
Dose 1-2mg weekly
Frequency Once or twice weekly (e.g., Monday/Thursday for split dosing)
Cycle 8-12 weeks
Storage Lyophilized: 2-8°C refrigerated; Reconstituted: 2-8°C refrigerated, use within 30 days
Accumulation Plotter

Community Research

Join others researching CJC-1295 with DAC — share findings, ask questions, and learn from real experiences

View Results Aggregated community findings
Discussion Questions & experiences
Submit Your Findings Contribute your research data

Modified growth hormone releasing hormone engineered for extended duration via albumin-binding technology. DAC binds to albumin, extending half-life and providing continuous GHRH receptor stimulation.

Mechanism of Action

DAC binds to albumin, extending half-life to 6-8 days and providing continuous GHRH receptor stimulation for sustained GH/IGF-1 elevation.

01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes

Molecular Data

Molecular Weight
3,647.28 Da
Chain Length
30 amino acids
Type
GHRH analog with DAC
Amino Acid Sequence
One-letter: YADAIFTNSYRKVLAQLSARKLLQDILSRK
H₂N
Y 1
O ‖ C
N
A 2
O ‖ C
N
D 3
O ‖ C
N
A 4
O ‖ C
N
I 5
O ‖ C
N
F 6
O ‖ C
N
T 7
O ‖ C
N
N 8
O ‖ C
N
S 9
O ‖ C
N
Y 10
O ‖ C
N
R 11
O ‖ C
N
K 12
O ‖ C
N
V 13
O ‖ C
N
L 14
O ‖ C
N
A 15
O ‖ C
N
Q 16
O ‖ C
N
L 17
O ‖ C
N
S 18
O ‖ C
N
A 19
O ‖ C
N
R 20
O ‖ C
N
K 21
O ‖ C
N
L 22
O ‖ C
N
L 23
O ‖ C
N
Q 24
O ‖ C
N
D 25
O ‖ C
N
I 26
O ‖ C
N
L 27
O ‖ C
N
S 28
O ‖ C
N
R 29
O ‖ C
N
K 30
COOH
Tyr
1

Tyrosine

Position 1

Ala
2

Alanine

Position 2

Asp
3

Aspartic Acid

Position 3

Ala
4

Alanine

Position 4

Ile
5

Isoleucine

Position 5

Phe
6

Phenylalanine

Position 6

Thr
7

Threonine

Position 7

Asn
8

Asparagine

Position 8

Ser
9

Serine

Position 9

Tyr
10

Tyrosine

Position 10

Arg
11

Arginine

Position 11

Lys
12

Lysine

Position 12

Val
13

Valine

Position 13

Leu
14

Leucine

Position 14

Ala
15

Alanine

Position 15

Gln
16

Glutamine

Position 16

Leu
17

Leucine

Position 17

Ser
18

Serine

Position 18

Ala
19

Alanine

Position 19

Arg
20

Arginine

Position 20

Lys
21

Lysine

Position 21

Leu
22

Leucine

Position 22

Leu
23

Leucine

Position 23

Gln
24

Glutamine

Position 24

Asp
25

Aspartic Acid

Position 25

Ile
26

Isoleucine

Position 26

Leu
27

Leucine

Position 27

Ser
28

Serine

Position 28

Arg
29

Arginine

Position 29

Lys
30

Lysine

Position 30

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified
Peak 0.0 mcg
Trough 0.0 mcg
SS Peak 0.0 mcg
SS Trough 0.0 mcg

Research Indications

Growth Hormone
Sustained GH Elevation most effective

Continuous growth hormone release for 6-8 days per injection.

IGF-1 Optimization most effective

Significantly elevates IGF-1 levels for extended periods.

Convenience Protocol effective

Weekly dosing ideal for simple administration.

Body Composition
Fat Loss Enhancement effective

Continuous GH elevation promotes lipolysis and fat metabolism.

Lean Mass Gains effective

Sustained anabolic environment supports muscle protein synthesis.

Anti-Aging
Recovery Enhancement moderate

Accelerated healing and recovery from exercise or injury.

Dosing Protocols

Subcutaneous injection is the preferred route for DAC variant.

GoalDoseFrequencyRoute
Conservative Anti-Aging1mgOnce weeklySubQ
Standard Protocol2mgOnce weeklySubQ
Split Dosing1mgTwice weekly (Mon/Thu)SubQ
Loading Protocol2mg first week, then 1mgWeeklySubQ

Reconstitution Instructions

Materials Needed:
  • CJC-1295 with DAC peptide vial
  • Bacteriostatic water (2-5mL)
  • Insulin or 1mL syringes
  • Alcohol prep pads
  1. 1 Clean both vial tops with alcohol and dry completely
  2. 2 2mg vial: Add 1mL bacteriostatic water (creates 2mg/mL)
  3. 3 5mg vial: Add 2.5mL bacteriostatic water (creates 2mg/mL)
  4. 4 Inject water slowly to prevent foaming
  5. 5 Let sit 5 minutes before gently rolling to mix
  6. 6 Solution may appear slightly cloudy initially
  7. 7 Label with date and concentration immediately

Interactions

~
Ipamorelin
Continuous GH elevation may reduce synergistic benefits of pulsatile protocols.
monitor
~
GHRP-6
GHRP pulse effects diminished with continuous GH elevation.
monitor
!
CJC-1295 (without DAC)
Never combine different variants; choose based on desired release pattern.
avoid
!
MK-677
Both provide continuous GH elevation; combination risks excessive levels.
avoid
!
Tesamorelin
Both are GHRH analogs; no additional benefit and potential receptor competition.
avoid
!
HGH
Defeats purpose and may suppress natural production.
avoid
~
Sermorelin
CJC-1295 DAC is already more potent and long-lasting.
monitor

What to Expect

Week 1
Possible water retention, improved sleep, increased appetite
Week 2-3
Noticeable recovery improvements, some report joint discomfort
Week 4-6
Visible body composition changes, increased vascularity
Week 6-8
Continued improvements but watch for desensitization signs
Post-cycle
Most gains maintained; IGF-1 returns to baseline in 2-3 weeks

Side Effects & Safety

Common Side Effects

  • Water retention
  • Joint pain
  • Carpal tunnel symptoms

Stop Signs - Discontinue if:

  • Severe joint pain or carpal tunnel syndrome
  • Excessive water retention affecting daily life
  • Numbness or tingling in extremities
  • Significant blood glucose dysregulation
  • Signs of acromegaly (jaw growth, hand/feet enlargement)
  • Persistent lethargy indicating adrenal effects

Contraindications

  • Diabetes history
  • Cancer history
  • Predisposed sleep apnea

Quality Checklist

Good Signs

  • High purity requirement (>98%); impurities cause more side effects
  • Proper DAC labeling; legitimate products clearly state 'with DAC'

Warning Signs

  • Higher cost than non-DAC (2-3x more due to complex manufacturing)
  • Foaming during mixing is normal for DAC peptides; wait for foam to settle

Bad Signs

  • Extremely cheap pricing (if priced similar to non-DAC, likely mislabeled)
  • Clear solution immediately (should be slightly cloudy initially)

References

  • Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults
    Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Bhore R
    Journal of Clinical Endocrinology & Metabolism (2006)

    Subcutaneous CJC-1295 produced sustained, dose-dependent increases in GH and IGF-1 in healthy adults. Half-life of ~8 days. Cumulative effect after multiple doses with well-preserved GH pulsatility.

  • Pulsatile Secretion of Growth Hormone (GH) Persists During Continuous Stimulation by CJC-1295, a Long-Acting GH-Releasing Hormone Analog
    Ionescu M, Frohman LA
    Journal of Clinical Endocrinology & Metabolism (2006)

    Basal (trough) GH levels increased 7.5-fold. Mean GH levels increased 46% and IGF-1 levels increased 45%. Pulsatile GH secretion preserved despite continuous GHRH receptor stimulation.

  • Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog
    Jette L, Bhore R, Bhatt DL, et al.
    Endocrinology (2005)

    Identified CJC-1295 as a long-acting GHRH analog through albumin bioconjugation (DAC technology). Binds covalently to endogenous albumin, extending half-life from minutes to days.

  • Activation of the GH/IGF-1 Axis by CJC-1295, a Long-Acting GHRH Analog, Results in Serum Protein Profile Changes in Normal Adult Subjects
    Teichman SL, et al.
    Growth Hormone & IGF Research (2009)

    Long-acting GHRH stimulation via CJC-1295 produces measurable changes in serum protein profiles reflecting sustained GH/IGF-1 axis activation.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.